Trial reportMovement disorders : official journal of the Movement Disorder Society2018
A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease.
Trial report in Movement disorders : official journal of the Movement Disorder Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Double-Blind, Randomized, Placebo-Controlled Trial of DA-9701 in Parkinson's Disease: PASS-GI Study.Movement disorders : official journal of the Movement Disorder Society · 2020Trial
- The site of absorption matters: Small bowel dysmotility and levodopa pharmacokinetics in Parkinson's disease.Journal of Parkinson's disease · 2026Article
- Gastroparesis in Parkinson's disease: Diagnostic and clinical implications for optimizing pharmacological treatment.Journal of Parkinson's disease · 2026Review
- Management of Gastrointestinal Symptoms in Parkinson's Disease.Journal of central nervous system disease · 2025Review
- Gastric-filling ultrasonography to evaluate gastric motility in patients with Parkinson's disease.Frontiers in neurology · 2024Article
- Gastrointestinal Dysfunction in Parkinson's Disease: Neuro-Gastroenterology Perspectives on a Multifaceted Problem.Journal of movement disorders · 2023Article
- The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic.Nature reviews. Neurology · 2022Review
- Management of dysphagia and gastroparesis in Parkinson's disease in real-world clinical practice - Balancing pharmacological and non-pharmacological approaches.Frontiers in aging neuroscience · 2022Review
- Update to the Treatment of Parkinson's Disease Based on the Gut-Brain Axis Mechanism.Frontiers in neuroscience · 2022Review
- Parkinson disease and the gut: new insights into pathogenesis and clinical relevance.Nature reviews. Gastroenterology & hepatology · 2020Review
- Motilin: from gastric motility stimulation to hunger signalling.Nature reviews. Endocrinology · 2019Review
- Parkinson's Disease and Current Treatments for Its Gastrointestinal Neurogastromotility Effects.Current treatment options in gastroenterology · 2018Review
- A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research.Frontiers in pharmacology · 2018Review
Corrections and comments
- Commented on by
Authors and funding
11 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDelayed gastric emptying may impair l-dopa absorption, contributing to motor fluctuations. We evaluated the effect of camicinal (GSK962040), a gastroprokinetic, on the absorption of l-dopa and symptoms of PD.
methodsPhase II, double-blind, placebo-controlled trial. Participants were randomized to receive camicinal 50 mg once-daily (n = 38) or placebo (n = 20) for 7 to 9 days.
resultsl-dopa exposure was similar with coadministration of camicinal compared to placebo. Median time to maximum l-dopa concentration was reduced, indicating more rapid absorption of l-dopa. Camicinal resulted in significant reduction in OFF time (-2.31 hours; 95% confidence interval: -3.71, -0.90), significant increase in ON time (+1.88 hours; 95% confidence interval: 0.28, 3.48) per day, and significant decrease in mean total MDS-UPDRS score (-12.5; 95% confidence interval: -19.67, -5.29). Camicinal treatment was generally well tolerated.
conclusionsPD symptom improvement with camicinal occurred in parallel with more rapid absorption of l-dopa. This study provides evidence of an improvement of the motor response to l-dopa in people with PD treated with camicinal 50 mg once-daily compared with placebo, which will require further evaluation. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.